131 related articles for article (PubMed ID: 16282189)
1. Post-transplantation proteinuria and sirolimus.
Izzedine H; Brocheriou I; Frances C
N Engl J Med; 2005 Nov; 353(19):2088-9. PubMed ID: 16282189
[No Abstract] [Full Text] [Related]
2. Sirolimus damages podocytes in rats with protein overload nephropathy.
Cai Y; Chen Y; Zheng S; Chen B; Yang Y; Xia P
J Nephrol; 2011; 24(3):307-12. PubMed ID: 20954132
[TBL] [Abstract][Full Text] [Related]
3. High sirolimus levels may induce focal segmental glomerulosclerosis de novo.
Letavernier E; Bruneval P; Mandet C; Duong Van Huyen JP; Péraldi MN; Helal I; Noël LH; Legendre C
Clin J Am Soc Nephrol; 2007 Mar; 2(2):326-33. PubMed ID: 17699432
[TBL] [Abstract][Full Text] [Related]
4. Sirolimus reduces vasculopathy but exacerbates proteinuria in association with inhibition of VEGF and VEGFR in a rat kidney model of chronic allograft dysfunction.
Ko HT; Yin JL; Wyburn K; Wu H; Eris JM; Hambly BD; Chadban SJ
Nephrol Dial Transplant; 2013 Feb; 28(2):327-36. PubMed ID: 23229928
[TBL] [Abstract][Full Text] [Related]
5. Proteinuria in transplant patients associated with sirolimus.
Franco AF; Martini D; Abensur H; Noronha IL
Transplant Proc; 2007 Mar; 39(2):449-52. PubMed ID: 17362756
[TBL] [Abstract][Full Text] [Related]
6. Sirolimus interacts with pathways essential for podocyte integrity.
Letavernier E; Bruneval P; Vandermeersch S; Perez J; Mandet C; Belair MF; Haymann JP; Legendre C; Baud L
Nephrol Dial Transplant; 2009 Feb; 24(2):630-8. PubMed ID: 18927120
[TBL] [Abstract][Full Text] [Related]
7. Sirolimus and proteinuria in renal transplant patients: evidence for a dose-dependent effect on slit diaphragm-associated proteins.
Stallone G; Infante B; Pontrelli P; Gigante M; Montemurno E; Loverre A; Rossini M; Schena FP; Grandaliano G; Gesualdo L
Transplantation; 2011 May; 91(9):997-1004. PubMed ID: 21364499
[TBL] [Abstract][Full Text] [Related]
8. Temsirolimus-induced glomerulopathy.
Izzedine H; Boostandoot E; Spano JP; Bardier A; Khayat D
Oncology; 2009; 76(3):170-2. PubMed ID: 19212144
[TBL] [Abstract][Full Text] [Related]
9. Administration of pigment epithelium-derived factor (PEDF) reduces proteinuria by suppressing decreased nephrin and increased VEGF expression in the glomeruli of adriamycin-injected rats.
Fujimura T; Yamagishi S; Ueda S; Fukami K; Shibata R; Matsumoto Y; Kaida Y; Hayashida A; Koike K; Matsui T; Nakamura K; Okuda S
Nephrol Dial Transplant; 2009 May; 24(5):1397-406. PubMed ID: 19042927
[TBL] [Abstract][Full Text] [Related]
10. New insights into structural patterns encountered in glomerulosclerosis.
LeHir M; Kriz W
Curr Opin Nephrol Hypertens; 2007 May; 16(3):184-91. PubMed ID: 17420660
[TBL] [Abstract][Full Text] [Related]
11. mToR inhibitors-induced proteinuria: mechanisms, significance, and management.
Letavernier E; Legendre C
Transplant Rev (Orlando); 2008 Apr; 22(2):125-30. PubMed ID: 18631865
[TBL] [Abstract][Full Text] [Related]
12. Is sirolimus responsible for proteinuria?
Dervaux T; Caillard S; Meyer C; Ellero B; Woehl-Jaegle ML; Hannedouche T; Wolf P; Moulin B
Transplant Proc; 2005; 37(6):2828-9. PubMed ID: 16182822
[TBL] [Abstract][Full Text] [Related]
13. Proteinuria after conversion to sirolimus in renal transplant recipients.
Sahin GM; Sahin S; Kantarci G; Ergin H
Transplant Proc; 2006 Dec; 38(10):3473-5. PubMed ID: 17175308
[TBL] [Abstract][Full Text] [Related]
14. Podocyte foot process effacement in postreperfusion allograft biopsies correlates with early recurrence of proteinuria in focal segmental glomerulosclerosis.
Abdulnabi K; Hammad A; Sharma A; Mehra S; Ridgway D
Transplantation; 2013 Aug; 96(3):e11-2. PubMed ID: 23917686
[No Abstract] [Full Text] [Related]
15. Unusual post-transplantation recurrence of focal segmental glomerulosclerosis which resolved with cyclosporine but not with sirolimus.
Skhiri H; Morelon E; Noel LH; Mamzer-Bruneel MF; Legendre C; Peraldi MN; Kreis H
Transpl Int; 2005 Apr; 18(4):458-60. PubMed ID: 15773967
[TBL] [Abstract][Full Text] [Related]
16. Is sirolimus a nephrotoxic drug? A report of five cases.
Sabry AA; Elagroudy AE; El-dahshan KF; El-Rahim MA; Sobh MA
Transplant Proc; 2007 Jun; 39(5):1406-9. PubMed ID: 17580149
[No Abstract] [Full Text] [Related]
17. Mammalian target of rapamycin inhibition halts the progression of proteinuria in a rat model of reduced renal mass.
Diekmann F; Rovira J; Carreras J; Arellano EM; Bañón-Maneus E; Ramírez-Bajo MJ; Gutiérrez-Dalmau A; Brunet M; Campistol JM
J Am Soc Nephrol; 2007 Oct; 18(10):2653-60. PubMed ID: 17804674
[TBL] [Abstract][Full Text] [Related]
18. [The fate of podocytes in proteinuric nephropathies].
Ortiz A; Marrón B; Ramos A
Nefrologia; 2002; 22(5):425-31. PubMed ID: 12497743
[No Abstract] [Full Text] [Related]
19. Immunoexpression of podocyte-associated proteins in acquired human glomerulopathies with nephrotic syndrome.
Wagrowska-Danilewicz M; Stasikowska O; Danilewicz M
Pol J Pathol; 2006; 57(1):17-21. PubMed ID: 16739878
[TBL] [Abstract][Full Text] [Related]
20. Conversion to sirolimus from cyclosporine may induce nephrotic proteinuria and progressive deterioration of renal function in chronic allograft nephropathy patients.
Boratyńska M; Banasik M; Watorek E; Falkiewicz K; Patrzałek D; Szyber P; Klinger M
Transplant Proc; 2006; 38(1):101-4. PubMed ID: 16504675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
